Overview
TENNOR THERAP-B (6872)
TenNor Therapeutics (Suzhou) Limited engages in discovery, development and commercialization of differentiated therapies for diseases associated with bacterial...
- Open
- 75.650
- High
- 75.950
- Low
- 67.500
- Prev. Close
- 69.600
- Volume
- 19.90K
- Turnover
- 1.39M
- Avg Price
- 70.058
- Bid/Ask Ratio
- -66.67%
- Amplitude
- 12.14%
- 52wk High
- 287.000
- Volume Ratio
- 0.40
- Turnover Ratio
- 0.04%
- 52wk Low
- 62.250
- HK Mkt Cap
- 3.38B
- Market CapHKD
- 3.59B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -3.07
- EPSDynamic
- -2.83
- EPSStatic
- --
- BVPS
- 14.42
- P/B
- 4.76
- HK Shares
- 49.22M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 52.30M
- Min lot size
- 50
- Currency
- HKD
Daily Events
- Nov, 16
Tennor Therapeutics-B reversed early gains today, opening at HK$75.65 before sliding to HK$67.50 by 10:04 BJ and closing at HK$68.60, down 1.4% from HK$69.60, as the lift from the first Phase IIb patient enrollment for rifaquizinone in prosthetic joint infection and a buyback mandate of up to RMB50 million faded in thin trading; turnover was only HK$1.39 million and turnover rate 0.040%. Q2 EPS was a loss of HK$0.8585 and net loss HK$37.10 million, narrowing 13.37% year on year, while operating loss widened 47.12%, keeping the clinical-stage investment profile intact. The stock is down 67.49% year to date, 76.1% below its 52-week high of HK$287, just 10.2% above its 52-week low of HK$62.25, and below MA20 of HK$78.20 and MA60 of HK$119.03. Still, the buyback and clinical progress offer some support.
- Nov, 13
TenNor Therapeutics (6872.HK) spiked and faded, closing at HK$69.60, down 2.11%, after an early probe to HK$72.00 met no follow-through buying and the afternoon slid to HK$67.25 before a late repair; turnover was just 39,750 shares worth HK$2.75 million, a 0.08% turnover rate, so existing buyback and incentive news no longer moved a thin tape. Incremental flow was limited to the board-approved H-share buyback of up to RMB 50 million and the related next-day disclosure return, plus shareholder approval of the 2026 H-share award scheme, while first-patient enrolment in the Phase IIb rifaquizinone trial for prosthetic joint infection was already digested. Fundamentals remain loss-making: Q2 2026 EPS was -HK$0.8585 with a net loss of HK$37.1 million, narrowing 13.37% year on year, while operating loss widened 47.12%. The stock is down 67.01% year to date, 75.75% below its June 23 high of HK$287 and only 11.81% above its November 2 low of HK$62.25, and sits well under its MA20 of HK$79.85. Though at 4.83x PB and HK$3.64 billion market value, the very thin volume leaves it prone to outsized swings.
- Nov, 10
Tennor Therapeutics-B closed at HK$71.50, up 1.85% from HK$70.20, in a spike-and-fade session: an early 09:35 high of HK$73.60 gave way to HK$69.10 by 10:08, with the afternoon recovering to HK$71.70 on thin volume of 30,100 shares. Support comes from steady buybacks — 25,200 shares repurchased across the four sessions from Oct 27 to Nov 5 for about HK$2.0 million — alongside first-patient enrollment in the Phase IIb trial of TNP-2092 intra-articular injection for prosthetic joint infection. Fundamentals remain loss-making: Q2 2026 EPS of -HK$0.8585, a net loss of HK$37.1 million, and an operating loss widening 47.12% year on year with ROE at -19.62%. The stock sits 14.86% above its Nov 2 52-week low of HK$62.25 but below MA20 of HK$84.88 and MA60 of HK$127.15, down 66.11% year to date and 75.09% below the June 23 high of HK$287. However, single-session turnover is extremely thin, limiting the signal value of the tape.
- Nov, 9
Tennor Therapeutics-B rose 6.36% to HK$70.20 from a HK$66.00 prior close, opening lower, spiking to HK$71.80 at 10:29 BJ and then fading through the afternoon session, on thin volume of 55,050 shares worth HK$3.83mn. Buybacks and pipeline news supplied the catalysts: the company spent HK$322,000, HK$340,500 and HK$280,900 on 5,000, 5,000 and 4,000 shares on 3-5 November, while TNP-2092 has selected intra-articular injection for prosthetic joint infection as its priority indication and the first patient has been enrolled in the Phase IIb trial. Fundamentals remain pre-revenue: Q2 EPS was -HK$0.8585 and the net loss of HK$37.1mn narrowed 13.37% year on year, yet the operating loss of HK$35.5mn widened 47.12%, with ROE at -19.62%. The stock is down 66.73% year to date, 75.54% below its 23 June 52-week high of HK$287, and still sits under its MA20 of HK$86.45 and MA60 of HK$129.28, only 12.77% above the 2 November low of HK$62.25. Though turnover of 0.11% and buybacks small against a HK$3.67bn market value suggest the move is a thin-liquidity impulse rather than a trend.
- Nov, 6
Tennor Therap-B fell 5.71% to HK$66.00 in a spike-and-fade session: it opened flat at HK$70.00, slid to an intraday low of HK$65.45 at 13:01 BJ and closed near the day's trough on turnover of just 38,900 shares (about HK$2.6 million) and a 0.08% turnover rate, thin liquidity amplifying the move. The retreat extends the digestion of the late-October catalyst, first patient dosing in the Phase IIb trial of TNP-2092 intra-articular injection for prosthetic joint infection, which had lifted the stock more than 10% in a single session before two straight drops of 13% and 6%. Buybacks of 5,000, 5,000 and 4,000 shares on Nov 3-5, roughly HK$943,000 combined, were too small to support the price. Fundamentals remain loss-making: Q2 EPS -HK$0.8585 and a net loss of HK$37.1 million, narrowed 13.37% year on year, while the operating loss widened 47.12%. At HK$66.00 the shares sit 77% below the 52-week high of HK$287, down 68.72% YTD, below the MA20 of 88.24 and MA60 of 131.43, at 4.58x book, and only 6% above the 52-week low of HK$62.25, though the repeated buybacks still absorb some supply.
News
Market Movers · TENNOR THERAP-B rose approximately 9%
Weekly Review · Weekly Recap | TENNOR THERAP-B -0.85%, R&D updates on core products
PUBT · TenNor Therapeutics Enrolls First Patient in Phase IIb Rifaquizinone Trial for Prosthetic Joint Infection
Market Movers · Tennor Therapeutics climbs 6%
Market Movers · Tennor Therapeutics drops 6% in Hong Kong trading
PUBT · Tennor Therapeutics Files HKEX Next-Day Disclosure Return Announcing Share Buyback
